True Wealth Design’s Arcutis Biotherapeutics ARQT Stock Holding History

True Wealth Design’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.1K	Hold	80	–	–	﹤0.01%	1672
2026 Q1	$1.89K	Hold	80	–	–	﹤0.01%	1570
2025 Q4	$2.32K	Hold	80	–	–	﹤0.01%	1397
2025 Q3	$1.51K	Buy	+80	New	+$1.26K	﹤0.01%	1586
2025 Q2	–	Sell	-9	Closed	-$141	–	2585
2025 Q1	$141	Buy	+9	New	+$127	﹤0.01%	2087
2024 Q4	–	Sell	-111	Closed	-$1.03K	–	1364
2024 Q3	$1.03K	Buy	+111	New	+$1.09K	﹤0.01%	967

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

True Wealth Design's ARQT Position: Q2 2026 in Review

True Wealth Design held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 80 shares worth $2.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1672.

True Wealth Design first reported a position in ARQT in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.32K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

True Wealth Design held 80 shares of Arcutis Biotherapeutics worth $2.1K as of Q2 2026.
True Wealth Design left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1672 holding.
True Wealth Design first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
True Wealth Design's Arcutis Biotherapeutics position peaked at $2.32K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.